SCHEMBL5147289

SCHEMBL5147289

O=C1NC(=S)NC1=Cc1ccc(-c2ccc(C(=O)O)c(Cl)c2)o1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 9/20 0.76
GSK3B P49841 9/20 0.76
AURKA O14965 1/20 0.64
AURKB Q96GD4 1/20 0.64
SIRT2 Q8IXJ6 1/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 2/20 0.60
POLB P06746 2/20 0.60
MAPT P10636 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
LMNA P02545 1/20 0.60
PLA2G1B P04054 1/20 0.60
DNMT1 P26358 1/20 0.60
APEX1 P27695 1/20 0.60
RECQL P46063 1/20 0.60
ATG4B Q9Y4P1 1/20 0.60
BRAF P15056 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147286 1.00 GSK3A (0.76) GSK3AGSK3BAURKAAURKBSIRT2
SCHEMBL5145131 0.91 GSK3A (0.76) GSK3AGSK3BAURKAAURKBSIRT2
SCHEMBL5145124 0.91 GSK3A (0.76) GSK3AGSK3BAURKAAURKBSIRT2
SCHEMBL5145235 0.90 AURKA (0.78) GSK3AGSK3BAURKAAURKBSIRT2
SCHEMBL15506584 0.86 GSK3A (1.00) GSK3AGSK3BSIRT2MEN1KMT2A
SCHEMBL5145152 0.81 GSK3A (0.78) GSK3AGSK3BSIRT2MEN1KMT2A
SCHEMBL5145154 0.81 GSK3A (0.78) GSK3AGSK3BSIRT2MEN1KMT2A
SCHEMBL5143164 0.80 GSK3A (1.00) GSK3AGSK3BAURKAAURKBMEN1
SCHEMBL5143166 0.80 GSK3A (1.00) GSK3AGSK3BAURKAAURKBMEN1
SCHEMBL1435462 0.78 AURKA (1.00) GSK3AGSK3BAURKAAURKBSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 GSK3A 2087/4885GSK3B 2118/4885AURKA 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.